Liver Fibrosis Market Size By Treatment (ACE Inhibitors, Peroxisome Proliferator-Activated Receptors (PPAR)-Alpha Agonists, Hepatotropic Drugs, and Others), By Condition (Chronic Liver Diseases, Hepatitis C, and Nonalcoholic Steatohepatitis), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others), Regions, Segmentation, and Projection till 2030
CAGR: 11.4%Current Market Size: USD 18.32 BillionFastest Growing Region: APAC
Largest Market: North AmericaProjection Time: 2023-2030Base Year: 2022
Global Liver Fibrosis Market- Market Overview:
The global liver fibrosis market is expected to grow from USD 18.32 billion in 2022 to USD 43.45 billion by 2030, at a CAGR of 11.4% during the Projection period 2023-2030. The growth of this market is mainly driven owing to the rising geriatric population and investment in healthcare infrastructure.
An excess of extracellular matrix proteins, including collagen, occurs in most chronic liver diseases that result in liver fibrosis. There are abnormally large quantities of scar tissue in the liver when there is repeated or continuous damage to it, which results in liver fibrosis. Fibrosis does not present symptoms, but severe scarring results in cirrhosis, which in turn leads to symptoms. The condition is not characterized by symptoms, but extensive scarring can lead to cirrhosis, which is characterized by symptoms. In order to determine how serious the condition is, healthcare providers conduct blood tests, imaging tests, and liver biopsy procedures. In order to stop or slow further scarring of the liver, healthcare practitioners focus on treating the source of liver fibrosis. Physiologically, liver fibrosis manifests as the deposition of extracellular matrix (ECM) by myofibroblasts. Myofibroblasts are not found in a healthy liver and gather in an injured liver. Increasing investment in developing advanced technologies as well as emerging industries present opportunities for market growth. The market growth is also expected to be driven by an increase in R&D activities along with an increase in drug approvals and launches during the Projection period, as well as the increase of government-led initiatives to treat liver cirrhosis.
Sample Request: - Global Liver Fibrosis Market
Market Dynamics:
Drivers:
- Rising geriatric population
A surging geriatric population is estimated to drive the market's expansion during the Projection period. According to the World Health Organization (WHO), over 524 million geriatrics were estimated in 2010 and are expected to reach nearly 2 billion by 2050. Moreover, geriatrics suffer from liver fibrosis more frequently than other populations because of their compromised immune systems.
Restraints:
- Lack of skilled professionals
Developing economies face a restraining factor in the market due to the lack of skilled professionals and a lack of healthcare infrastructure. Additionally, the implementation of strict government regulations impedes market growth. Furthermore, during the Projection period, low screening rates and low awareness of treatment will also limit the market growth.
Opportunities:
- Technological advancements
Market growth can be attributed to the growth of emerging industries and increased investment in advanced technologies. In addition, the increased R&D activities and drug approvals & launches are propelling the market growth during the Projection period. Additionally, government-sponsored initiatives are also helping to drive market growth in liver cirrhosis treatment.
Challenges:
- High cost
As a result of the high cost of the treatment, the market is expected to grow slowly. The growth rate of the market will also be impacted by strict regulatory policies and a lack of awareness among people throughout the Projection period.
Segmentation Analysis:
The global liver fibrosis market has been segmented based on treatment, condition, distribution channel, and region.
By Treatment
The treatment segment includes ACE inhibitors, peroxisome proliferator-activated receptors (PPAR)-alpha agonists, hepatotropic drugs, and others. The hepatotropic drugs segment led the largest share of the liver fibrosis market with a market share of around 56.3% in 2022. A 29.16% market share was held by hepatotropic drugs in 2021, a figure attributed to increasing awareness of new drugs. Moreover, hepatitis is a medical condition affecting mainly the liver, which can also affect the digestive system and the brain over the long term. There are three main types of hepatitis - HCV, HBV, and HAV.
By Condition
The condition segment includes chronic liver diseases, hepatitis C, and nonalcoholic steatohepatitis. The hepatitis C segment led the largest share of the liver fibrosis market with a market share of around 45.3% in 2022. As a result of multiple companies participating in developing treatments and medications for hepatitis C, this segment dominated the market in 2021 with 41.12%. Additionally, the increased number of government initiatives and the increased awareness of treating hepatitis C is helping to propel the segment's market growth.
By Distribution Channel
The distribution channel segment includes hospital pharmacy, online pharmacy, retail pharmacy, and others. The hospital pharmacy segment led the largest share of the liver fibrosis market with a market share of around 37.3% in 2022. The hospital pharmacy segment dominated the global market in 2021, accounting for around 32.05% of global revenue. This growth is attributed to pharmacists' increased awareness.
Global Liver Fibrosis Market - Sales Analysis.
The sale of liver fibrosis expanded at a CAGR of 10.6% from 2016 to 2022.
In addition to the growing prevalence of liver fibrosis throughout the world, the market is projected to grow due to the surging prevalence of risk factors such as chronic hepatitis B or C infection, weak immune systems resulting from HIV co-infection, or use of immunosuppressive drugs after liver transplants.
Also, increasing efforts by private and public organizations to spread awareness about liver fibrosis will expand the market. Moreover, people are becoming sedentary, drinking more alcohol, and earning more disposable income, which will expand the market for liver fibrosis.
Furthermore, with non-contrast magnetic resonance imaging, physicians will be able to detect liver fibrosis types and infections related to the liver easily, helping them treat them accordingly.
Thus, owing to the aforementioned factors, the global liver fibrosis market is expected to grow at a CAGR of 11.4% during the Projection period from 2023 to 2030.
By Regional Analysis:
The regions analyzed for the liver fibrosis market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. The North American region dominated the liver fibrosis market and held a 38.6% share of the market revenue in 2022.
- The North American region witnessed a major share. Among the factors influencing North America's liver fibrosis market are the availability of innovative drug molecules and technological advancements in treatment. The market's growth rate will be further accelerated in this region by increasing healthcare expenditures and the presence of major key players.
- Asia Pacific is anticipated to experience significant growth during the predicted period. A growing prevalence of chronic liver diseases such as nonalcoholic fatty liver disease and others is expected to drive growth in Asia Pacific during the Projection period. The rapidly developing economies and rapidly evolving healthcare infrastructure also propel market growth in this region. Additionally, the growing medical tourism industry and increasing disposable income contribute to market growth.
Global Glucose Meter Market - Country Analysis:
- Germany
Germany's liver fibrosis market size was valued at USD 1.3 billion in 2022 and is expected to reach USD 3.1 billion by 2030, at a CAGR of 11.5% from 2023 to 2030.
It is also anticipated that the market will continue to grow due to various technological advancements in imaging techniques, and Y-O-Y increases in patients diagnosed with liver diseases. It is predicted that mergers and acquisitions will shape the face of the market better during the Projection period as a result of the increasing number of mergers and acquisitions occurring between companies. In addition to the expiration of licenses for some drugs, the market is also fueled by robust pipeline drugs for liver diseases.
- China
China’s liver fibrosis market size was valued at USD 1.42 billion in 2022 and is expected to reach USD 3.44 billion by 2030, at a CAGR of 11.7% from 2023 to 2030.
In this country, the market is growing because of the high prevalence of liver diseases and healthcare expenditure, the presence of key players, and the high R&D investments. Also influencing the market growth in this country are favourable reimbursement scenarios, an increase in awareness about new treatment options, and a developed regulatory framework.
- India
India's liver fibrosis market size was valued at USD 1.09 billion in 2022 and is expected to reach USD 2.6 billion by 2030, at a CAGR of 11.6% from 2023 to 2030.
The development of healthcare infrastructure propels market growth in the country. In addition, government and non-government awareness programs related to liver disease also contribute to market growth.
Key Industry Players Analysis:
To increase their market position in the global liver fibrosis market business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, partnerships, joint ventures, etc.
- Zydus Therapeutics
- Akero Therapeutics Inc.
- Enyo Pharma
- Madrigal Pharmaceuticals
- Lipocine Inc.
- Axcella Therapeutics
- Novartis AG
- Sanofi
- Pharmaxis Ltd
- HighTide Biopharma
- Galmed Research and Development
- Intercept Pharmaceuticals
- Rivus Pharmaceuticals Inc.
- Sagimet Biosciences Inc.
- Novo Nordisk A/S
- Bristol-Myers Squibb Company
- Pfizer Inc.
Latest Development:
- In January 2022, A new test for detecting liver fibrosis (ELF) has been launched by Siemens Healthineers. This test allows for widespread clinical access to a minimally invasive prognostic tool, The ELF Test is a simple, accurate blood test for determining a patient's prognosis in individuals with advanced fibrosis (F3 or F4) caused by non-alcoholic steatohepatitis (NASH), a non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation.
- In December 2021, Continent Pharmaceutical Co, Ltd, a pharmaceutical company, successfully completed Phase II clinical trials for Hydronidone capsules in January 2022, and was promoted to phase 3 clinical trials. The phase 3 clinical trial studies for Hydronidone capsules are currently underway and are expected to conclude in June 2024.
Report Metrics
|
Report Attribute |
Details |
|
Study Period |
2022-2030 |
|
Base year |
2022 |
|
CAGR (%) |
11.4% |
|
Market Size |
18.32 billion in 2022 |
|
Projection period |
2023-2030 |
|
Projection unit |
Value (USD) |
|
Segments covered |
By Treatment, By Condition, By Distribution Channel, and By Region. |
|
Report Scope |
Revenue Projection, competitive landscape, company ranking, growth factors, and trends |
|
Companies covered |
Zydus Therapeutics, Akero Therapeutics Inc., Enyo Pharma, Madrigal Pharmaceuticals, Lipocine Inc., Axcella Therapeutics, Novartis AG, Sanofi, Pharmaxis Ltd, HighTide Biopharma, Galmed Research and Development, Intercept Pharmaceuticals, Rivus Pharmaceuticals Inc., Sagimet Biosciences Inc., Novo Nordisk A/S, Bristol-Myers Squibb Company, and Pfizer Inc. |
|
By Treatment |
|
|
By Condition |
|
|
By Distribution Channel |
|
|
Regional scope |
|
Scope of the Report
Global Liver Fibrosis Market by Treatment:
- ACE Inhibitors
- Peroxisome Proliferator-Activated Receptors (PPAR)-Alpha Agonists
- Hepatotropic Drugs
- Others
Global Liver Fibrosis Market by Condition:
- Chronic Liver Diseases
- Hepatitis C
- Nonalcoholic Steatohepatitis
Global Liver Fibrosis Market by Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Global Liver Fibrosis Market by Region:
- North America
- USA
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Asia-Pacific
- Japan
- China
- India
- Korea
- Southeast Asia
- South America
- Brazil
- Peru
- Middle East and Africa
- UAE
- South Africa
- Saudi Arabia
Frequently Asked Questions
What will be the expected market size of the liver fibrosis market in 2030?
Global liver fibrosis market is expected to reach USD 43.45 billion by 2030, at a CAGR of 11.4% from 2023 to 2030.
What are the driving factors of the liver fibrosis market?
Rising geriatric population and technological advancements.
Which region will witness more growth in the liver fibrosis market?
North American region will witness more growth in the liver fibrosis market.
What are the segments covered in the liver fibrosis market report?
The segments covered in the liver fibrosis market are; treatment, condition, distribution channel, and region.
Which are the leading market players active in the liver fibrosis market?
Leading players in the liver fibrosis market are Zydus Therapeutics, Akero Therapeutics Inc., Enyo Pharma, Madrigal Pharmaceuticals, Lipocine Inc., Axcella Therapeutics, Novartis AG, Sanofi, Pharmaxis Ltd, HighTide Biopharma, Galmed Research and Development, Intercept Pharmaceuticals, Rivus Pharmaceuticals Inc., Sagimet Biosciences Inc., Novo Nordisk A/S, Bristol-Myers Squibb Company, Pfizer Inc. among others.
- Introduction
- 1. Objectives of the Study
- 2. Market Definition
- 3. Research Scope
- Research Methodology and Assumptions
- Executive Summary
- Premium Insights
- 1. Porter’s Five Forces Analysis
- 2. Value Chain Analysis
- 3. Top Investment Pockets
- 3.1. Market Attractiveness Analysis by Treatment
- 3.2. Market Attractiveness Analysis by Condition
- 3.3. Market Attractiveness Analysis by Distribution Channel
- 3.4. Market Attractiveness Analysis by Region
- 4. Industry Trends
- Market Dynamics
- 1. Market Evaluation
- 2. Drivers
- 2.1. Rising geriatric population
- 3. Restraints
- 3.1. Lack of skilled professionals
- 4. Opportunities
- 4.1. Technological advancements
- 5. Challenges
- 5.1. High cost
- Global Liver Fibrosis Market Analysis and Projection, By Treatment
- 1. Segment Overview
- 2. ACE Inhibitors
- 3. Peroxisome Proliferator-Activated Receptors (PPAR)-Alpha Agonists
- 4. Hepatotropic Drugs
- 5. Others
- Global Liver Fibrosis Market Analysis and Projection, By Condition
- 1. Segment Overview
- 2. Chronic Liver Diseases
- 3. Hepatitis C
- 4. Nonalcoholic Steatohepatitis
- Global Liver Fibrosis Market Analysis and Projection, By Distribution Channel
- 1. Segment Overview
- 2. Hospital Pharmacy
- 3. Online Pharmacy
- 4. Retail Pharmacy
- 5. Others
- Global Liver Fibrosis Market Analysis and Projection, By Regional Analysis
- 1. Segment Overview
- 2. North America
- 2.1. U.S.
- 2.2. Canada
- 2.3. Mexico
- 3. Europe
- 3.1. Germany
- 3.2. France
- 3.3. U.K.
- 3.4. Italy
- 3.5. Spain
- 4. Asia-Pacific
- 4.1. Japan
- 4.2. China
- 4.3. India
- 5. South America
- 5.1. Brazil
- 6. Middle East and Africa
- 6.1. UAE
- 6.2. South Africa
- Global Liver Fibrosis Market-Competitive Landscape
- Overview
- Market Share of Key Players in the Liver Fibrosis Market
- 2.1. Global Company Market Share
- 2.2. North America Company Market Share
- 2.3. Europe Company Market Share
- 2.4. APAC Company Market Share
- Competitive Situations and Trends
- 3.1. Technology Launches and Developments
- 3.2. Partnerships, Collaborations, and Agreements
- 3.3. Mergers & Acquisitions
- 3.4. Expansions
- Company Profiles
- Zydus Therapeutics
- 1.1. Business Overview
- 1.2. Company Snapshot
- 1.3. Company Market Share Analysis
- 1.4. Company Technology Portfolio
- 1.5. Recent Developments
- 1.6. SWOT Analysis
- Akero Therapeutics Inc.
- 2.1. Business Overview
- 2.2. Company Snapshot
- 2.3. Company Market Share Analysis
- 2.4. Company Technology Portfolio
- 2.5. Recent Developments
- 2.6. SWOT Analysis
- Enyo Pharma
- 3.1. Business Overview
- 3.2. Company Snapshot
- 3.3. Company Market Share Analysis
- 3.4. Company Technology Portfolio
- 3.5. Recent Developments
- 3.6. SWOT Analysis
- Madrigal Pharmaceuticals
- 4.1. Business Overview
- 4.2. Company Snapshot
- 4.3. Company Market Share Analysis
- 4.4. Company Technology Portfolio
- 4.5. Recent Developments
- 4.6. SWOT Analysis
- Lipocine Inc.
- 5.1. Business Overview
- 5.2. Company Snapshot
- 5.3. Company Market Share Analysis
- 5.4. Company Technology Portfolio
- 5.5. Recent Developments
- 5.6. SWOT Analysis
- Axcella Therapeutics
- 6.1. Business Overview
- 6.2. Company Snapshot
- 6.3. Company Market Share Analysis
- 6.4. Company Technology Portfolio
- 6.5. Recent Developments
- 6.6. SWOT Analysis
- Novartis AG
- 7.1. Business Overview
- 7.2. Company Snapshot
- 7.3. Company Market Share Analysis
- 7.4. Company Technology Portfolio
- 7.5. Recent Developments
- 7.6. SWOT Analysis
- Sanofi
- 8.1. Business Overview
- 8.2. Company Snapshot
- 8.3. Company Market Share Analysis
- 8.4. Company Technology Portfolio
- 8.5. Recent Developments
- 8.6. SWOT Analysis
- Pharmaxis Ltd
- 9.1. Business Overview
- 9.2. Company Snapshot
- 9.3. Company Market Share Analysis
- 9.4. Company Technology Portfolio
- 9.5. Recent Developments
- 9.6. SWOT Analysis
- HighTide Biopharma
- Business Overview
- Company Snapshot
- Company Market Share Analysis
- Company Technology Portfolio
- Recent Developments
- SWOT Analysis
- Galmed Research and Development
- Business Overview
- Company Snapshot
- Company Market Share Analysis
- Company Technology Portfolio
- Recent Developments
- SWOT Analysis
- Intercept Pharmaceuticals
- Business Overview
- Company Snapshot
- Company Market Share Analysis
- Company Technology Portfolio
- Recent Developments
- SWOT Analysis
- Rivus Pharmaceuticals Inc.
- Business Overview
- Company Snapshot
- Company Market Share Analysis
- Company Technology Portfolio
- Recent Developments
- SWOT Analysis
- Sagimet Biosciences Inc.
- Business Overview
- Company Snapshot
- Company Market Share Analysis
- Company Technology Portfolio
- Recent Developments
- SWOT Analysis
- Novo Nordisk A/S
- Business Overview
- Company Snapshot
- Company Market Share Analysis
- Company Technology Portfolio
- Recent Developments
- SWOT Analysis
- Bristol-Myers Squibb Company
- Business Overview
- Company Snapshot
- Company Market Share Analysis
- Company Technology Portfolio
- Recent Developments
- SWOT Analysis
- Pfizer Inc.
- Business Overview
- Company Snapshot
- Company Market Share Analysis
- Company Technology Portfolio
- Recent Developments
- SWOT Analysis
- Zydus Therapeutics
List of Table
- Global Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Global ACE Inhibitors, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Peroxisome Proliferator-Activated Receptors (PPAR)-Alpha Agonists, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Hepatotropic Drugs, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Others, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Global Chronic Liver Diseases, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Hepatitis C, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Nonalcoholic Steatohepatitis, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Global Hospital Pharmacy, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Online Pharmacy, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Retail Pharmacy, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Others, Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- Global Liver Fibrosis Market, By Region, 2023–2030 (USD Billion)
- North America Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- North America Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- North America Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- USA Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- USA Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- USA Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Canada Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Canada Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Canada Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Mexico Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Mexico Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Mexico Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Europe Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Europe Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Europe Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Germany Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Germany Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Germany Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- France Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- France Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- France Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- UK Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- UK Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- UK Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Italy Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Italy Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Italy Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Spain Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Spain Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Spain Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Asia Pacific Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Asia Pacific Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Asia Pacific Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Japan Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Japan Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Japan Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- China Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- China Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- China Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- India Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- India Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- India Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- South America Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- South America Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- South America Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Brazil Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Brazil Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Brazil Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- Middle East and Africa Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- Middle East and Africa Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- Middle East and Africa Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- UAE Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- UAE Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- UAE Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
- South Africa Liver Fibrosis Market, By Treatment, 2023–2030 (USD Billion)
- South Africa Liver Fibrosis Market, By Condition, 2023–2030 (USD Billion)
- South Africa Liver Fibrosis Market, By Distribution Channel, 2023–2030 (USD Billion)
List of Figures
- Global Liver Fibrosis Market Segmentation
- Liver Fibrosis Market: Research Methodology
- Market Size Estimation Methodology: Bottom-Up Approach
- Market Size Estimation Methodology: Top-Down Approach
- Data Triangulation
- Porter’s Five Forces Analysis
- Value Chain Analysis
- Global Liver Fibrosis Market Attractiveness Analysis by Treatment
- Global Liver Fibrosis Market Attractiveness Analysis by Condition
- Global Liver Fibrosis Market Attractiveness Analysis by Distribution Channel
- Global Liver Fibrosis Market Attractiveness Analysis by Region
- Global Liver Fibrosis Market: Dynamics
- Global Liver Fibrosis Market Share by Treatment (2023 & 2030)
- Global Liver Fibrosis Market Share by Condition (2023 & 2030)
- Global Liver Fibrosis Market Share by Distribution Channel (2023 & 2030)
- Global Liver Fibrosis Market Share by Regions (2023 & 2030)
- Global Liver Fibrosis Market Share by Company (2021)
Choose License Type
GreyViews is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.
